Author:
Mathew Matthen,Enzler Thomas,Shu Catherine A.,Rizvi Naiyer A.
Subject
Pharmacology (medical),Pharmacology
Reference63 articles.
1. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non–small-cell lung cancer;Antonia;Journal of Clinical Oncology,2016
2. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;New England Journal of Medicine,2017
3. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy;Apetoh;Nature Medicine,2007
4. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC);Besse;European Journal of Cancer,2015
5. Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non–small-cell lung cancer;Borghaei,2017
Cited by
93 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献